# Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

> **NCT03478514** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 39 (actual)

## Conditions studied

- Mantle Cell Lymphoma
- B Cell Lymphoma

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03478514
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-11
- **Primary completion:** 2025-11-10
- **Final completion:** 2026-08-30
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03478514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03478514, "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03478514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*